Qiagen N.V. reaffirmed earnings guidance for the year 2024. For the year, the company has reaffirmed its outlook for net sales of at least $2.0 billion CER.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.88 USD | +0.07% | +2.00% | +0.24% |
Jun. 06 | Qiagen Scraps NeuMoDx 96, 288 Molecular Systems; Raises 2024 Adjusted Earnings Outlook | MT |
Jun. 06 | Qiagen to Discontinue NeuMoDx Integrated PCR Testing System | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.24% | 9.96B | |
+49.41% | 56.95B | |
+39.61% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024